Symphogen A/S

Core Business and Therapeutic Focus

The fundamental activity of Symphogen revolves around leveraging the power of the natural immune system by creating precisely defined mixtures of multiple monoclonal antibodies (mAbs). This approach, which results in multiclonal antibodies, is designed to mimic the diversity and binding capability of the body's natural polyclonal immune response while maintaining the consistency and manufacturability of monoclonal antibodies. By targeting multiple epitopes???distinct sites on a single antigen???with different antibodies, Symphogen's therapeutics aim to overcome mechanisms of resistance and enhance efficacy, particularly in complex diseases like cancer.

Symphogen???s research and early development activities span the entire process of generating these differentiated antibody therapeutics. Its strategic focus areas include: * Oncology and Immuno-Oncology: The company is dedicated to developing novel compounds, either as stand-alone or combination therapies, for difficult-to-treat cancers. Its pipeline has historically addressed a wide range of cancer types, including solid tumor malignancies, metastatic colorectal cancer (mCRC), and lung cancer. * Historical Diversification: While current strategy is centered on cancer, Symphogen's historical pipeline has also included therapeutic candidates for immunoglobulin replacement and infectious diseases, demonstrating the broad applicability of its multiclonal antibody platform.

Products and Services

Symphogen's offerings consist of its innovative multiclonal antibody candidates and its proprietary drug discovery and manufacturing technology platforms, which it has utilized in various collaborative partnerships.

Multiclonal Antibody Pipeline (Select Examples)

The company???s product pipeline is built upon its multiclonal technology, yielding drug candidates that are mixtures of meticulously selected monoclonal antibodies:

• Sym004: This multiclonal antibody mixture was developed to target the Epidermal Growth Factor Receptor (EGFR) by binding to non-overlapping epitopes. It was studied in a randomized Phase 2 trial for patients with refractory metastatic colorectal cancer (mCRC). The mechanism is designed to block ligand binding and induce the potent removal of the target receptor from the cell surface (receptor down-modulation).
• Rozrolimupab (Sym001): As a historical lead product, Sym001 is a recombinant polyclonal antibody consisting of twenty-five distinct monoclonal antibodies. It was developed for the treatment of various hematological diseases, such as Idiopathic Thrombocytopenic Purpura (ITP) and Hemolytic disease of the newborn, and received Orphan Drug designation from the United States Food and Drug Administration (FDA).
• Anti-MET Clinical Program: Symphogen has also initiated a clinical program for an anti-MET multiclonal antibody, further expanding its oncology-focused therapeutic candidates.

Proprietary Technology Platforms

The company's in-house technological capabilities are central to its operations and are often leveraged in its collaborative activities. These include:

• Symplex Technology (Drug Discovery Platform): This platform is the company???s proprietary engine for identifying and selecting the individual monoclonal antibodies that constitute the therapeutic mixture. The technology enables the discovery of new antibodies against specific disease targets.
• Sympress Technology (Manufacturing Platform): Sympress is the robust manufacturing platform designed to produce recombinant antibody mixtures, or "recombinant polyclonal antibodies," in high yields. The technology utilizes Chinese hamster ovary (CHO) cell lines to produce consistent mixtures with high batch-to-batch reproducibility at industrial scale, thereby overcoming the quality control challenges associated with traditional polyclonal antibody sources.

Services and Capabilities

As the antibody Centre of Excellence for Servier, Symphogen provides internal expertise and capabilities that cover the entire early-stage biologic drug development process:

• Antibody Discovery and Research: Utilizing its advanced technologies, including antibody libraries, next-generation platforms, and bioinformatics tools, Symphogen performs cutting-edge biologics research.
• Early Clinical Stages Development: The company manages the progression of its novel compounds through early-phase clinical trials.
• CMC (Chemistry, Manufacturing, and Controls) Biologics Development: Symphogen's capabilities span from research to market authorization, including the process development necessary for large-scale and consistent production of their complex multiclonal antibody products.

Strategic Alliances and Collaborations

Symphogen has a history of engaging in strategic alliances to accelerate the development and commercialization of its product candidates and technology. Notable collaborations have included: * Genentech, Inc.: A collaboration pact to utilize the Symplex technology platform for discovering new antibodies against infectious disease targets. * Merck KGaA: Licensing and collaboration agreements concerning its oncology product pipeline. * Baxalta (now Shire): A strategic collaboration to accelerate innovation, particularly in the immuno-oncology field. * Meiji Seika Kaisha, Ltd.: A collaboration and license agreement for the development and commercialization of Sym006. * NIAID/NIH: Grants for developmental programs, such as Sym002, a recombinant polyclonal antibody candidate against smallpox.